Moderna accepted $2.5 billion in taxpayer money to develop its Covid-19 vaccine. But officials in the U.S. and overseas are having trouble persuading the company to license its technology.
Tag: Public-Private Sector Cooperation
Rich Countries Signed Away a Chance to Vaccinate the World
Despite warnings, American and European officials gave up leverage that could have guaranteed access for billions of people. That risks prolonging the pandemic.
Where Europe Went Wrong in Its Vaccine Rollout, and Why
While Washington went into business with the drug companies, Europe was more fiscally conservative and trusted the free market.
White House Weighs New Cybersecurity Approach After Failure to Detect Hacks
The intelligence agencies missed massive intrusions by Russia and China, forcing the administration and Congress to look for solutions, including closer partnership with private industry.
Governments Sign Secret Vaccine Deals. Here’s What They Hide.
Multibillion-dollar contracts give drug makers liability shields, patent ownership and leeway on delivery dates and pricing — and promises that much of it will not be made public.
Five Takeaways From the Developing Space War Between China and the U.S.
The Biden administration is inheriting the menace of Chinese antisatellite arms as well as an innovative way of trying to defuse the escalating threat.
How Space Became the Next ‘Great Power’ Contest Between the U.S. and China
The Biden administration faces not only waves of Chinese antisatellite weapons but a history of jumbled responses to the intensifying threat.
Scientists Debate New Covid-19 Vaccination Tactics as Rollout Falters
Should second doses be delayed? Should most adults receive half-doses? Scientists are pondering ways to get more shots into more arms.
F.D.A. Clears Moderna’s Covid Vaccine
The Food and Drug Administration authorized a second coronavirus vaccine for emergency use, clearing the way for millions more Americans to be immunized next week.
Moderna and Pfizer Begin Late-Stage Coronavirus Vaccine Trials
The studies each aim to enroll 30,000 people and determine whether the vaccines are safe and effective.